Molecular Mechanisms of Resistance in Metastatic Colorectal Cancer

Resistance to systemic therapies in metastatic colorectal cancer arises through a spectrum of molecular adaptations that allow tumour cells to evade the effects of targeted agents. Primary resistance often reflects pre-existing genomic alterations, such as activating mutations in RAS or BRAF, or amplifications of receptor tyrosine kinases that bypass epidermal growth factor receptor (EGFR) blockade. Acquired resistance emerges under selective pressure from treatment, with resistant clones harbouring secondary mutations in RAS genes, the EGFR extracellular domain or downstream effectors of the MAPK pathway. Non-genetic mechanisms also contribute, including phenotypic switching to fibroblast-rich stromal states, paracrine signalling via stress-induced exosomes carrying ligands such as amphiregulin, and epigenetic reprogramming that sustains alternative growth factor pathways. Circulating tumour DNA (ctDNA) profiling has revealed the dynamic rise and fall of resistance mutations, enabling real-time monitoring of clonal evolution. Strategies to overcome resistance focus on vertical suppression of the EGFR pathway by combining inhibitors of EGFR and downstream kinases, rechallenge with anti-EGFR antibodies guided by ctDNA clearance, and the development of next-generation anti-EGFR agents or antibody conjugates that recruit innate immunity. Integrative insights into the interplay between genetic and microenvironmental factors are driving the design of adaptive therapies to forestall or reverse treatment failure.

Research from Nature Portfolio

Recent studies have harnessed ctDNA analysis to refine patient selection and rechallenge strategies. A 2024 trial demonstrated that absence of ctDNA alterations across a broad panel of resistance genes identifies patients most likely to benefit from first-line anti-EGFR therapy, prolonging overall survival compared with antivascular regimens. The CHRONOS trial applied an interventional liquid biopsy approach to exclude patients with emergent RAS, BRAF or EGFR mutations, then rechallenged the remaining cohort with panitumumab, achieving disease control in over 60% of cases. Foundational work has delineated the clonal dynamics underlying resistance to EGFR antibodies: patients with deeper and longer initial responses most often acquire EGFR extracellular domain mutations, whereas those with smaller tumour shrinkage preferentially develop RAS mutations, a pattern mirrored in circulating cell-free DNA and linked to distinct clinical outcomes.

Molecular Mechanisms of Resistance in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in molecular mechanisms of resistance in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Circulating tumour DNA (ctDNA): fragmented DNA shed by tumour cells into the bloodstream, used for non-invasive genomic profiling and monitoring of resistance mutations.

Epidermal growth factor receptor (EGFR) blockade: therapeutic inhibition of EGFR signalling by monoclonal antibodies or small-molecule inhibitors to halt tumour proliferation.

RAS mutations: activating alterations in KRAS, NRAS or HRAS genes that render downstream MAPK signalling independent of EGFR input.

Exosomes: nanoscale extracellular vesicles secreted by cells, carrying proteins, RNAs and ligands that modulate the tumour microenvironment and drug response.

Clonal evolution: process by which distinct subpopulations of tumour cells with advantageous mutations expand under therapeutic pressure, leading to resistance.

References

1. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nature Medicine (2024).
2. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nature Medicine (2022).
3. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications (2016).
4. Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology (2023).
5. Stress‐induced Rab11a‐exosomes induce amphiregulin‐mediated cetuximab resistance in colorectal cancer. Journal of Extracellular Vesicles (2024).
6. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study. EBioMedicine (2024).
7. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications (2015).
8. Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies. Advanced Science (2024).